Three Year Anniversary of the Introduction of Deucravacitinib to the US Market
Main Article Content
Keywords
Deucravacitinib, Janus kinase inhibitor, psoriasis, lupus
References
2. Armstrong AW, Lebwohl M, Warren RB, et al. Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials. J Eur Acad Dermatol Venereol. 2025;39(7):1336-1351. doi:10.1111/jdv.20553
3. Mima Y, Yamamoto M, Iozumi K. Deucravacitinib Treatment for Psoriasis Complicated by Myelodysplastic Syndrome Without Exacerbation of the Underlying Hematologic Disorder: A Case Report. Cureus. 2025;17(5):e84075. Published 2025 May 14. doi:10.7759/cureus.84075
4. Armstrong AW, Kircik L, Stein Gold L, et al. Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials. Dermatol Ther (Heidelb). 2025;15(4):1025-1035. doi:10.1007/s13555-025-01362-w
5. HIGHLIGHTS of PRESCRIBING INFORMATION. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214958s000lbl.pdf
6. Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29-39. doi:10.1016/j.jaad.2022.07.002
7. Lebwohl M, Bukhalo M, Stein Gold L, et al. A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement. J Am Acad Dermatol. 2024;91(6):1150-1157. doi:10.1016/j.jaad.2024.07.1521
8. Hagino T, Onda M, Saeki H, Fujimoto E, Kanda N. Effectiveness of deucravacitinib for genital, nail and scalp lesions in patients with psoriasis: a 24-week real-world study. Clin Exp Dermatol. 2024;50(1):130-133. doi:10.1093/ced/llae312
9. Guénin S, Andrews E, Lebwohl MG. Safety and efficacy of dual tyrosine kinase 2 inhibitor and monoclonal antibody therapy for psoriasis and psoriatic arthritis. Br J Dermatol. 2024;190(3):451-453. doi:10.1093/bjd/ljad473
10. Mease PJ, Deodhar AA, van der Heijde D, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022;81(6):815-822. doi:10.1136/annrheumdis-2021-221664
11. Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2023;75(2):242-252. doi:10.1002/art.42391
12. Bokor LA, Martyin K, Krebs M, et al. Deucravacitinib shows superior efficacy and safety in cutaneous lupus erythematosus compared to various biologics and small molecules - A systematic review and meta-analysis. Autoimmun Rev. 2025;24(3):103723. doi:10.1016/j.autrev.2024.103723
13. Matthew EJ, Verma KK, Paulger B. Oral Deucravacitinib for Treatment-Refractory Cutaneous Lupus Erythematosus. Cureus. 2025;17(3):e81539. Published 2025 Mar 31. doi:10.7759/cureus.81539
14. Ezeh N, Vleugels RA, Shahriari N. Discoid lupus erythematosus successfully treated with deucravacitinib. JAAD Case Rep. 2024;49:59-61. Published 2024 Apr 30. doi:10.1016/j.jdcr.2024.04.032
15. Bouché N, Al-Saedy MA, Song EJ. Successful treatment of refractory subacute cutaneous lupus erythematosus with deucravacitinib. JAAD Case Rep. 2023;39:93-95. Published 2023 Aug 4. doi:10.1016/j.jdcr.2023.07.030
16. Assaf K, Patt S, Schäfer VS, Wenzel J, Novak N, Wilsmann-Theis D. Successful treatment of subacute cutaneous lupus erythematosus with the TYK-2 inhibitor deucravacitinib in a patient with concomitant psoriasis vulgaris. J Dtsch Dermatol Ges. 2025;23(7):874-877. doi:10.1111/ddg.15705
17. Aw K, Gavigan G. Treatment of discoid lupus erythematosus scarring alopecia with deucravacitinib: A case report. SAGE Open Med Case Rep. 2025;13:2050313X241304891. Published 2025 Jan 2. doi:10.1177/2050313X241304891
18. Kurz B, Ivanova I, Drexler K, Berneburg M, Günther F, Niebel D. Rapid clinical improvement of refractory subacute cutaneous lupus erythematosus with oral tyrosine kinase 2 inhibitor deucravacitinib: A case report. J Eur Acad Dermatol Venereol. 2024;38(5):e434-e436. doi:10.1111/jdv.19667
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.